Veracyte, Inc. (VCYT)

NASDAQ: VCYT · Real-Time Price · USD
39.20
+0.05 (0.13%)
Nov 20, 2024, 4:00 PM EST - Market closed
0.13%
Market Cap 3.04B
Revenue (ttm) 425.33M
Net Income (ttm) -9.27M
Shares Out 77.50M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE 43.09
Dividend n/a
Ex-Dividend Date n/a
Volume 631,375
Open 39.16
Previous Close 39.15
Day's Range 38.61 - 39.80
52-Week Range 18.61 - 41.43
Beta 1.67
Analysts Strong Buy
Price Target 40.00 (+2.04%)
Earnings Date Nov 6, 2024

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis sy... [Read more]

Sector Healthcare
IPO Date Oct 30, 2013
Employees 815
Stock Exchange NASDAQ
Ticker Symbol VCYT
Full Company Profile

Financial Performance

In 2023, Veracyte's revenue was $361.05 million, an increase of 21.76% compared to the previous year's $296.54 million. Losses were -$74.40 million, 103.5% more than in 2022.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for VCYT stock is "Strong Buy." The 12-month stock price forecast is $40.0, which is an increase of 2.04% from the latest price.

Price Target
$40.0
(2.04% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

14 days ago - Seeking Alpha

Veracyte Announces Third Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024. "The strong momentum across our testing bu...

14 days ago - Business Wire

Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. UBS Healthc...

21 days ago - Business Wire

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 ...

5 weeks ago - Business Wire

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate C...

2 months ago - Business Wire

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte appoints Brent Shafer and Tom Miller, Ph.D., to its board of directors.

2 months ago - Business Wire

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate ...

3 months ago - Business Wire

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte is Named a Greater Bay Area Top Workplace by the San Francisco Chronicle.

3 months ago - Business Wire

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million.

3 months ago - Benzinga

Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript

Veracyte, Inc. (NASDAQ:VCYT) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Shayla Gorman – Senior Director, Investor Relations Marc Stapley – Chief Executive Officer...

3 months ago - Seeking Alpha

Veracyte Announces Second Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2024. “Our exceptional second quarter results are a ...

3 months ago - Business Wire

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2024 after the close of market on Tuesday, ...

4 months ago - Business Wire

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors.

6 months ago - Business Wire

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer.

6 months ago - Business Wire

Veracyte Announces First Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024. “We had a strong start to 2024, driven by robu...

7 months ago - Business Wire

14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients.

7 months ago - Business Wire

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, M...

7 months ago - Business Wire

New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance.

7 months ago - Business Wire

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024.

7 months ago - Business Wire

Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines.

9 months ago - Business Wire

Veracyte, Inc. (VCYT) Q4 2023 Earnings Call Transcript

Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET

9 months ago - Seeking Alpha

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023. “We closed 2023 with another...

9 months ago - Business Wire

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and John Leite, Ph.D., chief commercial officer, CLIA, will pres...

9 months ago - Business Wire

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2023 after the close of market o...

10 months ago - Business Wire

Veracyte Completes Acquisition of C2i Genomics

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Completes Acquisition of C2i Genomics.

10 months ago - Business Wire